Trial · NCT02874846
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
NCT02874846, Phase 2, Completed, Aerie Pharmaceuticals; results first posted 2018-04-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution. Trials, record NCT02874846. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02874846
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
- NCT number
- NCT02874846
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Aerie Pharmaceuticals
- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- First posted
- 2016-08-22
- Last updated
- 2018-04-17
- Results first posted
- 2018-04-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Intraocular Pressure (IOP) Over Nocturnal Time Period | Assessed over 24 hours at 9 pm, midnight, 3 am and 6 am on days 1/2 and 8/9 | The primary efficacy endpoint was the mean change from baseline in mean nocturnal IOP (defined as the mean of the 4 nocturnal time points: 21:00, 00:00, 03:00, and 06:00 hours) on Day 8/Day 9 |
| Secondary | Number of Participants With Adverse Events as a Measure of Safety and Tolerability | 7 days (day 1/2 to day 8/9) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Intraocular Pressure (IOP) Over Nocturnal Time Period | Assessed over 24 hours at 9 pm, midnight, 3 am and 6 am on days 1/2 and 8/9 | ITT | mmHg | MEAN |
| SECONDARY | Number of Participants With Adverse Events as a Measure of Safety and Tolerability | 7 days (day 1/2 to day 8/9) | ITT | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Intraocular Pressure (IOP) Over Nocturnal Time Period | Netarsudil Ophthalmic Solution 0.02% | Baseline (Day 1/2); nocturnal mean | 22.84 | Standard Deviation 2.21 | mmHg |
| Change in Intraocular Pressure (IOP) Over Nocturnal Time Period | Netarsudil Ophthalmic Solution Vehicle | Baseline (Day 1/2); nocturnal mean | 23.56 | Standard Deviation 1.94 | mmHg |
| Change in Intraocular Pressure (IOP) Over Nocturnal Time Period | Netarsudil Ophthalmic Solution 0.02% | Visit 4 (Day 8/9); nocturnal mean | 19.38 | Standard Deviation 2.86 | mmHg |
| Change in Intraocular Pressure (IOP) Over Nocturnal Time Period | Netarsudil Ophthalmic Solution Vehicle | Visit 4 (Day 8/9); nocturnal mean | 23.19 | Standard Deviation 1.95 | mmHg |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Netarsudil Ophthalmic Solution 0.02% | 0 | Participants | ||
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Netarsudil Ophthalmic Solution Vehicle | 0 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Netarsudil Ophthalmic Solution 0.02% | 8 | |
| Overall Study | STARTED | Netarsudil Ophthalmic Solution Vehicle | 4 | |
| Overall Study | COMPLETED | Netarsudil Ophthalmic Solution 0.02% | 8 | |
| Overall Study | COMPLETED | Netarsudil Ophthalmic Solution Vehicle | 4 | |
| Overall Study | NOT COMPLETED | Netarsudil Ophthalmic Solution 0.02% | 0 | |
| Overall Study | NOT COMPLETED | Netarsudil Ophthalmic Solution Vehicle | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Netarsudil Ophthalmic Solution 0.02% | 0 | 8 |
| Total, all-cause mortality | Netarsudil Ophthalmic Solution Vehicle | 0 | 4 |
| Total, other adverse events | Netarsudil Ophthalmic Solution 0.02% | 0 | 8 |
| Total, other adverse events | Netarsudil Ophthalmic Solution Vehicle | 0 | 4 |
| Total, serious adverse events | Netarsudil Ophthalmic Solution 0.02% | 0 | 8 |
| Total, serious adverse events | Netarsudil Ophthalmic Solution Vehicle | 0 | 4 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33244711 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Netarsudil Ophthalmic Solution 0.02% vs Netarsudil Ophthalmic Solution Vehicle: Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Trial comparisons |
| Netarsudil Ophthalmic Solution 0.02% vs Netarsudil Ophthalmic Solution Vehicle: deaths from any cause | Trial comparisons |
| Netarsudil Ophthalmic Solution 0.02% vs Netarsudil Ophthalmic Solution Vehicle: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02874846
GET https://conductscience.org/api/trials/v1/NCT02874846/registered